AbbVie Inc (ABBV)vsAssembly Biosciences Inc (ASMB)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
ASMB
Assembly Biosciences Inc
$22.90
-5.02%
HEALTHCARE · Cap: $485.32M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 88257% more annual revenue ($62.82B vs $71.10M). ABBV leads profitability with a 5.8% profit margin vs -9.0%. ABBV trades at a lower P/E of 105.1x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ASMB
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Margin of Safety
+34.0%
Fair Value
$41.47
Current Price
$22.90
$18.57 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
ROE of -3.2% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : ASMB
The strongest argument for ASMB centers on Debt/Equity, Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : ASMB
The primary concerns for ASMB are EPS Growth, Market Cap, P/E Ratio. A P/E of 306.1x leaves little room for execution misses.
Key Dynamics to Monitor
ABBV profiles as a value stock while ASMB is a turnaround play — different risk/reward profiles.
ASMB carries more volatility with a beta of 1.09 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 23/100) and 12.4% revenue growth. ASMB offers better value entry with a 34.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Assembly Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Assembly Biosciences, Inc. is a clinical-stage biotechnology company in the United States. The company is headquartered in South San Francisco, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?